-
1
-
-
0026432631
-
Nephrotoxic potential of Bence Jones proteins
-
Soloman A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins [see comments]. N Eng J Med 1991;324:1845.
-
(1991)
N Eng J Med
, vol.324
, pp. 1845
-
-
Soloman, A.1
Weiss, D.T.2
Kattine, A.A.3
-
2
-
-
0028834450
-
Role of light chain variable region in myeloma with light chain deposition disease: Evidence from an experimental model
-
Khamlichi AA, Rocca A, Touchard G, et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 1995;86:3655.
-
(1995)
Blood
, vol.86
, pp. 3655
-
-
Khamlichi, A.A.1
Rocca, A.2
Touchard, G.3
-
3
-
-
0029008826
-
Renal disease and patient survival in light chain deposition disease
-
Pozzi C, Fogazzi GB, Banfi G, et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995;43:281.
-
(1995)
Clin Nephrol
, vol.43
, pp. 281
-
-
Pozzi, C.1
Fogazzi, G.B.2
Banfi, G.3
-
4
-
-
0028276963
-
Monoclonal proteins and renal disease
-
Kyle RA. Monoclonal proteins and renal disease. Annu Rev Med 1994;45:71.
-
(1994)
Annu Rev Med
, vol.45
, pp. 71
-
-
Kyle, R.A.1
-
5
-
-
0032992602
-
Renal failure and multiple myeloma: Pathogenesis and treatment of renal failure and management of underlying myeloma
-
Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999;13:79-90.
-
(1999)
Blood Reviews
, vol.13
, pp. 79-90
-
-
Clark, A.D.1
Shetty, A.2
Soutar, R.3
-
6
-
-
0033922451
-
Renal involvement in multiple myeloma: A 10-year study
-
Sakhuja V, Jha V, Varma S, et al. Renal involvement in multiple myeloma: a 10-year study. Renal Failure 2000;22:465-77.
-
(2000)
Renal Failure
, vol.22
, pp. 465-477
-
-
Sakhuja, V.1
Jha, V.2
Varma, S.3
-
7
-
-
6844252283
-
Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events
-
Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J Clin Oncol 1998;16:593-602.
-
(1998)
J Clin Oncol
, vol.16
, pp. 593-602
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
8
-
-
0036729485
-
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
-
Berenson JR, Hillner BE, Kyle R, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3719-3736
-
-
Berenson, J.R.1
Hillner, B.E.2
Kyle, R.3
-
10
-
-
0028963248
-
Peripheral blood stem cell transplant for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
-
Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplant for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588.
-
(1995)
Blood
, vol.85
, pp. 588
-
-
Tricot, G.1
Jagannath, S.2
Vesole, D.3
-
11
-
-
0029804411
-
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma
-
Govindarajan R, Jagannath S, Flick JT et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95:349-53.
-
(1996)
Br J Haematol
, vol.95
, pp. 349-353
-
-
Govindarajan, R.1
Jagannath, S.2
Flick, J.T.3
-
12
-
-
0028150642
-
Multiple myeloma: Why does the disease escape from plateau phase?
-
Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994;88:667-71.
-
(1994)
Br J Haematol
, vol.88
, pp. 667-671
-
-
Joshua, D.E.1
Brown, R.D.2
Gibson, J.3
-
13
-
-
0030005782
-
Plateau phase in multiple myeloma: An analysis of long-term follow-up of 432 patients
-
Divanen TM for the Finnish leukemia group. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br J Haematol 1996;92:834-9.
-
(1996)
Br J Haematol
, vol.92
, pp. 834-839
-
-
Divanen, T.M.1
-
14
-
-
0023870374
-
A randomized trial of maintenance versus maintenance melphalan and prednisone in responding multiple myeloma patients
-
Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988;57:94-9.
-
(1988)
Br J Cancer
, vol.57
, pp. 94-99
-
-
Belch, A.1
Shelley, W.2
Bergsagel, D.3
-
15
-
-
0028951419
-
IFN alpha-2b versus no maintenance treatment during the plateau phase in multiple myeloma: A randomized study
-
Westin J, Rodjer S, Turesson I, et al. IFN alpha-2b versus no maintenance treatment during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995;89:561-8.
-
(1995)
Br J Haematol
, vol.89
, pp. 561-568
-
-
Westin, J.1
Rodjer, S.2
Turesson, I.3
-
16
-
-
0029099343
-
Randomized trial of IFN maintenance in multiple myeloma: A study of the Canada Clinical Trials group
-
Browman GP, Bergsagel DE, et al. Randomized trial of IFN maintenance in multiple myeloma: a study of the Canada Clinical Trials group. J Clin Oncol 1995;13:2354-60.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2354-2360
-
-
Browman, G.P.1
Bergsagel, D.E.2
-
17
-
-
8944220233
-
A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
-
Intergroupe Francais du Myelome
-
Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Eng J Med 1996;335:91-7.
-
(1996)
N Eng J Med
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
-
18
-
-
0038147912
-
Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94)
-
abstract 7
-
Attal M, Harousseau JL, Facon T, et al. Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94). Blood 2002;100:abstract 7.
-
(2002)
Blood
, vol.100
-
-
Attal, M.1
Harousseau, J.L.2
Facon, T.3
-
19
-
-
0030043438
-
Graft-versus-myeloma effect: Proof of principle
-
Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8.
-
(1996)
Blood
, vol.87
, pp. 1196-1198
-
-
Tricot, G.1
Vesole, D.H.2
Jagannath, S.3
-
20
-
-
0033844816
-
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
-
Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-7.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3031-3037
-
-
Lokhorst, H.M.1
Schattenberg, A.2
Cornelissen, J.J.3
-
21
-
-
4244105378
-
An overview of allogeneic stem cell transplantation in multiple myeloma
-
May, Banff, CAN
-
Gahrton G, Apperley J, Bacigalupo A, et al. An overview of allogeneic stem cell transplantation in multiple myeloma. VIIIth International Myeloma Workshop, S14, May 2001, Banff, CAN.
-
(2001)
VIIIth International Myeloma Workshop
-
-
Gahrton, G.1
Apperley, J.2
Bacigalupo, A.3
-
22
-
-
0029822773
-
Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
-
Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787-93.
-
(1996)
Blood
, vol.88
, pp. 2787-2793
-
-
Bensinger, W.I.1
Buckner, C.D.2
Anasetti, C.3
-
23
-
-
0000054477
-
Outcome of unrelated transplants in patients with multiple myeloma
-
abstract 1780
-
Ballen K, King R, Carston M, Reece D, Giralt S, Vesole D, et al. Outcome of unrelated transplants in patients with multiple myeloma. Blood 2000;96:abstract 1780, 414a.
-
(2000)
Blood
, vol.96
-
-
Ballen, K.1
King, R.2
Carston, M.3
Reece, D.4
Giralt, S.5
Vesole, D.6
-
24
-
-
0001190342
-
Allogeneic bone marrow transplantation in multiple myeloma: Single-center experience of 97 patients
-
abstract 993
-
Mehta J, Ayers D, Mattox S, et al. Allogeneic bone marrow transplantation in multiple myeloma: single-center experience of 97 patients. Blood 1997; 90: abstract 993, 225a.
-
(1997)
Blood
, vol.90
-
-
Mehta, J.1
Ayers, D.2
Mattox, S.3
-
25
-
-
85112358324
-
Allogeneic bone marrow transplantation: Role of T cell depletion and graft versus host disease
-
abstract 862
-
Huff CA, Noga SJ, Jones RJ et al. Allogeneic bone marrow transplantation: Role of T cell depletion and graft versus host disease. Blood 2000; 96: abstract 862,202a.
-
(2000)
Blood
, vol.96
-
-
Huff, C.A.1
Noga, S.J.2
Jones, R.J.3
-
26
-
-
85112398073
-
Allogeneic peripheral blood stem cell Transplantation for patients with multiple myeloma - Single centre experience
-
abstract 5276
-
Cheung B, Ackers C, Powles R, et al. Allogeneic peripheral blood stem cell Transplantation for patients with multiple myeloma - single centre experience. Blood 2000;96:abstract 5276,352b.
-
(2000)
Blood
, vol.96
-
-
Cheung, B.1
Ackers, C.2
Powles, R.3
-
27
-
-
4243330156
-
Graft versus myeloma. Clinical and basic aspects
-
May, Banff, CAN
-
Lokhorst H. Graft versus myeloma. Clinical and basic aspects. VIIIth International Myeloma Workshop, S20, May 2001, Banff, CAN.
-
(2001)
VIIIth International Myeloma Workshop
-
-
Lokhorst, H.1
-
28
-
-
0033021543
-
Reinventing bone marrow transplantation: Nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect
-
Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect. Oncology 1999;13:621-8.
-
(1999)
Oncology
, vol.13
, pp. 621-628
-
-
Champlin, R.1
Khouri, I.2
Kornblau, S.3
-
29
-
-
85112386084
-
Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience
-
abstract 872
-
Lalancette M, Rezvani K, Szydlo R et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: the EBMT experience. Blood 2000;96: abstract 872.
-
(2000)
Blood
, vol.96
-
-
Lalancette, M.1
Rezvani, K.2
Szydlo, R.3
-
30
-
-
0035353184
-
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
-
Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-9.
-
(2001)
Blood
, vol.97
, pp. 2574-2579
-
-
Badros, A.1
Barlogie, B.2
Morris, C.3
-
31
-
-
0003300168
-
Nonmyeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma
-
abstract 3379
-
Peggs KS, Williams CD, Chopra R, D'Sa S, et al. Nonmyeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma. Blood 2000;96:abstract 3379,781a.
-
(2000)
Blood
, vol.96
-
-
Peggs, K.S.1
Williams, C.D.2
Chopra, R.3
D'Sa, S.4
-
32
-
-
85112376366
-
Mini-allografts as salvage therapy in patients with heavily pretreated multiple myeloma
-
abstract 5066
-
Schaefer H, Bader P, Hebart H et al. Mini-allografts as salvage therapy in patients with heavily pretreated multiple myeloma. Blood 2000;96:abstract 5066, 306b.
-
(2000)
Blood
, vol.96
-
-
Schaefer, H.1
Bader, P.2
Hebart, H.3
-
33
-
-
0003274693
-
Non-myeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma
-
abstract 1549
-
Giralt S, Weber D, Aleman A, et al. Non-myeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma. Blood 1999;94:abstract 1549, 347a.
-
(1999)
Blood
, vol.94
-
-
Giralt, S.1
Weber, D.2
Aleman, A.3
-
34
-
-
0028362802
-
Bone marrow angiogenesis and progression in multiple myeloma
-
Vacca A, Ribatti D, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
-
(1994)
Br J Haematol
, vol.87
, pp. 503-508
-
-
Vacca, A.1
Ribatti, D.2
-
35
-
-
0032748385
-
Anti-tumor activity of thalidomide in refractory multiple myeloma
-
Singhal S, Mehta J, Barlogie B, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Barlogie, B.3
-
36
-
-
0036843032
-
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
-
Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4319-4323
-
-
Rajkumar, S.V.1
Hayman, S.2
Gertz, M.A.3
-
37
-
-
0003251160
-
Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma
-
abstract 1400
-
Hussein MA, Karam MA, McLain DA, et al. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma. Blood 1999;94:abstract 1400.
-
(1999)
Blood
, vol.94
-
-
Hussein, M.A.1
Karam, M.A.2
McLain, D.A.3
|